RedHill Biopharma Files 6-K, Details H1 2024 Performance
Ticker: RDHL · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-update, agreement, product-sales
TL;DR
RedHill Biopharma 6-K out: H1 2024 sales for Movantik/Talicia detailed, global termination agreement signed July 15.
AI Summary
RedHill Biopharma Ltd. filed a 6-K report for the period ending June 30, 2024. The filing includes information related to its financial performance, including details on Movantik and Talicia sales for the first half of 2024 and 2023. It also mentions a Global Termination Agreement with Movantik Acquisition, Valinor Pharma LLC, HCR Redhill SPV LLC, effective July 15, 2024.
Why It Matters
This filing provides investors with an update on RedHill Biopharma's financial activities and key product sales, offering insights into the company's operational status for the first half of 2024.
Risk Assessment
Risk Level: medium — The filing contains financial performance data and agreements, which can impact investor decisions and stock valuation.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the timeframe for the financial data presented)
- 2024-07-15 — Global Termination Agreement Effective Date (Marks the start date of a significant contractual change)
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Filer of the 6-K report
- Movantik (product) — Product sales data included
- Talicia (product) — Product sales data included
- Global Termination Agreement (agreement) — Effective July 15, 2024
- Movantik Acquisition, Valinor Pharma LLC, HCR Redhill SPV LLC (company) — Parties to the Global Termination Agreement
FAQ
What were the sales figures for Movantik and Talicia in the first half of 2024?
The filing indicates sales data for Movantik and Talicia for the period of January 1, 2024, to June 30, 2024, and compares it to the same period in 2023.
When did the Global Termination Agreement become effective?
The Global Termination Agreement became effective on July 15, 2024.
Who are the parties involved in the Global Termination Agreement?
The parties mentioned in relation to the Global Termination Agreement are Movantik Acquisition, Valinor Pharma LLC, and HCR Redhill SPV LLC.
What is the primary purpose of this 6-K filing?
This 6-K filing serves as a report of foreign private issuer, providing updates on RedHill Biopharma Ltd.'s operations and financial information for the period ending June 30, 2024.
What is RedHill Biopharma Ltd.'s industry classification?
RedHill Biopharma Ltd. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 423 words · 2 min read · ~1 pages · Grade level 9.2 · Accepted 2024-08-29 07:07:16
Filing Documents
- rdhl-20240630x6k.htm (6-K) — 64KB
- rdhl-20240630xex99d1.htm (EX-99.1) — 237KB
- rdhl-20240630xex99d2.htm (EX-99.2) — 441KB
- rdhl-20240630xex99d1001.jpg (GRAPHIC) — 7KB
- 0001558370-24-012527.txt ( ) — 2825KB
- rdhl-20240630.xsd (EX-101.SCH) — 38KB
- rdhl-20240630_cal.xml (EX-101.CAL) — 39KB
- rdhl-20240630_def.xml (EX-101.DEF) — 105KB
- rdhl-20240630_lab.xml (EX-101.LAB) — 254KB
- rdhl-20240630_pre.xml (EX-101.PRE) — 164KB
- rdhl-20240630x6k_htm.xml (XML) — 335KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: August 29, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer 2